

The European Technology Platform Nanomedicine


Defining future activities of Nanomedicine in Europe

Patrick BOISSEAU

Programme Manager Nanomedicine, CEA-Leti, Grenoble (FR)

Chair of Working Group Nanodiagnostics, ETPN


Nanomedicine a cooperative & converging approach





Where is Nano in medicine

- Nanoparticles in diagnostics and therapy
- Nanoparticles for the delivery of drugs
- Surfaces on implants
- Materials in smart devices
- Scaffolds for cell and tissue engineering
- Sensing platform
- POC devices
- Medical Devices




→ Nano is only part of the story, but ...




Nano - in the molecular range

... it makes the story work!





Nanomedicine – key to diagnostic and preventive treatment



Through screening and diagnosis

- → identify disease early
- → earlier intervention



ETPN Analysis of status quo: Many challenges!

- History of lack of communication between Pharma & Academia
- Translational capacity often poor (Bench to Bed)
- Limited number of accessible safety labs
- Poor respect of GxPs
- Poor translation from Academia to Industry if not relevant to market.
- Paperwork & administration for FPx participation is tremendous
- Larger company guidance is essential for EC
- Need to engage with best academics, this is also an industrial priority
- ...



Tasks of the ETPN

Support EC & MS

Federate the Community

Nanomedicine Strategy Think-Tank

Services & support to the members

 Provide contact to industry, academia, etc


• Organise events, fora, etc

- Develop NM strategy,
- Prioritise topics, etc.
 - Provide 1st-hand info,
 - support consortia, collect feedback, etc.



2

The Basis of all: the ETPN member institutions





The ETPN's structure

Nano Diagnostics

Nanotechnology based diagnostics and imaging

Nano

Pharmaceutics

Nanotech for drug delivery, Nanodevices

Regenerative Medicine

Nanotechnology for regenerative medicine


3 technical Working Groups4 joint advisory groups

Extended Executive Board


Ethical and Social Aspects of Nanomedicine

Regulatory Framework

Intellectual Property Rights










ETPN as mediator – the translation triangle

- 1. Nanomedicine into clinical practice via industry
- 2. Align up-stream R&D with industrial needs
- Bridge academia and industry and clinicians on
 - ✓ Market needs
 - ✓ S&T bottlenecks
 - ✓ Approval process
 - ✓ Technology roadmaps

4. Suggest industry inspired call topics to the EC and to ERANET EuroNanoMed





The (Nano)medicine value chain



Applied Industrial Clinical **Patient** Basic Needs! Research R&D Implement. Implement. Clinical **Translation** Qualified Qualified Regulatory products products and services and services Issues Reimbursement

CLINAM aids





ETPN Think Tank towards FP8/ CSFRI

- ETPN contribution to the "Innovation Union" / "European Innovation Partnership on Active and Healthy Ageing" concept
- Analysis of future needs and Nanomedicine contribution
- ETPN Consultation document in preparation
- Online consultation on needs for the Common Strategic Framework for future EU Research and Innovation CSFRI Funding (FP8)





ETP Nanomedicine White Paper 2011

Improving Translation of Public Healthcare Nano-Research in Europe

Assessment

- Need to UNDERSTAND development processes,
- Need to DE-RISK innovation,
- Need to LEVERAGE capabilities,
- Need to REFOCUS projects
- Need to ADJUST funding allocation criteria and programmes.

Recommendations

- Implementing a dedicated translation oriented Nanomedicine funding programme
- 2. Establishing a novel translational Nanomedicine infrastructure
- 3. Selection of translatable research areas and definition of clear translatable research calls for Nanomedicine programme
- 4. Uptake of the translation principles into the review system for the Nanomedicine programme





The ETP Nanomedicine Action Plan

Goal → address today's needs for translation to make Europe competitive tomorrow

Part A: Initiative

- Defining Nanomedicine Programme
- Allocation sufficient funding
- Definition of comprehensive roadmaps

Part B: Community


- Uniting the Nanomedicine Community
- Interact with Regulatory Bodies (EMA & National)
- Involve Patient Groups

Part C: Infrastructure

Build Nanomedicine translation R&D Infrastructures

Part D: Measures

- Regulation
- Open Innovation approaches
- New approaches




Nano / Medicine Community





European Research Area - Positioning



ETPN, EPoSS and Photonics 21 can implement a cross-Initiative action in Health



More Info and Docs at:

... visit www.etp-nanomedicine.eu to

- Download publications
- Find further information
- Become a member
- ...







Thank you very much!

For more information visit: www.etp-nanomedicine.eu or contact secretariat@etp-nanomedicine.eu